• Rare earth supply chain innovator Ucore Rare Metals Inc. is working to strategically develop a North American-based supply chain for rare earth elements (“REEs”) that are vital to technologies ranging from smartphone to F-16 fighter jet parts
• China currently has a near-monopoly on REE refining and production, and international tech trade tensions in recent years have pushed Western nations to seek ways to revive their own REE industries
• Ucore has developed a proprietary RapidSX(TM) REE separation technology platform for refining rare earths, beginning with a strategic facility in development in Louisiana
• The company is celebrating announcement this month that it has completed the process for obtaining an 80 percent tax exemption for the next decade, pending the governor’s ratification of state and local authorities’ approvals

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a strategic metals supply chain-focused enterprise, is celebrating its advancing rare earth element (“REE”) project in Louisiana with the recent announcement that the company has received approvals from the Industrial Tax Exemption Program (“ITEP”) that will result in significant cost savings to Ucore.

Ucore has entered a multi-decade lease agreement with the administrators of the England Airpark in Alexandria, La., that will allow Ucore to build and operate a Strategic Metals Complex (“SMC”) where it will separate and produce REEs and oxides that are deemed critical to computer technology-based industries.

Currently, REE mining and refining are controlled by The People’s Republic of China to a degree that approaches a virtual monopoly. The European Union imports 98 percent of its REE supply from China and the United States gets 78 percent of its REE supply from China.

The industrial espionage and trade limit tensions of recent years between the United States and China have given rise to renewed efforts to maintain a Western hemisphere center to the supply chain for REE elements used in products ranging from cell phones to electric vehicles to F-35 fighter jets.

Ucore’s advancing SMC complex in Louisiana is central to the company’s plan to build that Western supply chain, starting with the refining of mined product.

“The overall State and local support we are receiving for the establishment of one of the first modern rare earth element processing facilities in North America has been an amazing experience, and we are diligently working to execute a Louisiana project that has the potential to significantly enhance the manufacturing landscape across North America as the world shifts to electrification,” Ucore Vice President and COO Mike Schrider stated in the company’s announcement about the tax exemption progress (https://ibn.fm/IzvFB).

According to the news release, the ITEP program offers up to a 10-year exemption to the company of 80 percent of the standard tax amount on a renewable five-year term, which may result in $8.2 million in projected tax savings for the company if the governor gives his final signature to the agreement.

Louisiana and the local parish have awarded the exemption based on Ucore’s commitment to create 100 family-wage paying jobs, its plans to make a capital investment of $75 million in the economy, and expectations that further statewide benefits for workers will be realized.

The company has been simultaneously engaged in establishing agreements for raw material supplies and supply off-take, as well as other financial arrangements.

The SMC complex will use Ucore’s proprietary RapidSX(TM) REE separation technology platform in a commercialization venture. RapidSX(TM) promises to improve on the industry standard for REE refining in terms of speed, environmental impact, and eventual cost factors. The company plans to produce 2,000 metric tons per year of total rare earth oxides (“TREOs”) by the beginning of 2025, growing to 5,000 tons by 2026 and 7,500 tons in 2027.

The company also owns an Alaskan rare earth mine prospect that it may eventually bring online to add to the limited American-based REE feedstock that currently exists.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Eloro Resources recently published its initial NI-43101 compliance mineral resource estimate (“MRE”)
• The company’s long-awaited MRE revealed the existence of total inferred mineral resources amounting to 670 million tonnes – equivalent to nearly $6.8 billion in value
• Whilst impressive, Eloro’s management has revealed that the company has more exploratory drilling work to continue towards the site’s western edge, with further mineral resource estimate enhancement remaining likely

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mining company focused on developing its potential world-class Iska Iska silver-tin polymetallic property located in the Potosi Department in southern Bolivia, recently updated the market with its initial mineral resource statement. Prepared in conjunction with mining consultancy Micon International Limited, Eloro announced that its exploratory drilling work had uncovered the existence of a ‘giant deposit’, amounting to nearly 300 million ounces of in situ silver, 4.1 million tonnes of zinc, 1.74 million tonnes of lead and 130,000 tonnes of tin boasting a cumulative in situ value of approximately $6.8 billion (https://ibn.fm/Hl4Yh). Interestingly, the company’s MRE attributed a value of $3.3bn to minerals located within the shallower, high-grade zone within the potential open pit, opening up the possibility of an earlier payback period than originally anticipated (https://ibn.fm/OkOdr).

Tom Larsen, CEO of Eloro, said: “We are delighted with this initial MRE which shows what a massive discovery Iska Iska is. The recent metallurgical work, particularly the positive “ore sorting” results, has significantly enhanced the potential economics by substantially lowering the NSR cutoff, especially for the potential open pit where the bulk of the resource is located. The fact that this potential pit is 1.4km in diameter and extends to a depth of 750m below the Santa Barbara hill attests to the remarkable size of the Iska Iska mineralized system.”

Larsen went on to additionally elaborate how the ongoing drilling work and subsequent initial mineral resource estimate publication was only a partial representation of the Iska Iska property’s total resources. Recent drilling at the adjoining Casiterita site, located 2km south-west of the original Santa Barbara zone returned a 0.17% presence of tin over 52.78m, implying that the overall extent of the Iska Iska mineralizing system was far more extensive than originally implied by the geophysical data. In particular, the company’s management went on to emphasize how the potential tin domain west of the original exploratory site remained extremely under-explored and would be subject to further testing during the next phase of drilling.

“Our geological team led by Dr. Bill Pearson, P.Geo., Vice President, Exploration, and Dr. Osvaldo Arce, P.Geo., General Manager of Minera Tupiza, are confident that the Iska Iska resource can be further expanded and that grades in areas with only wide-spaced drilling will likely increase with definition drilling. The tin domain in particular is very under-drilled, and our geophysical data indicates potential for a large tin porphyry at depth.”

Bolivia’s Cerro Rico de Potosi region has long been renowned for its prolific silver and tin deposits, with active mining operations carried out within the region dating as far back as the sixteenth century.  The recent discoveries at Iska Iska – a site nestled within Potosi’s fertile hills and product of a longstanding process that commenced with Eloro Resources exercising its option agreement to acquire the polymetallic property in early 2020 – holds great promise at a time when minerals such as tin and silver continue to enjoy skyrocketing demand – a result of the world’s ongoing drive towards renewable energy adoption. With its NI-43101 report now published and further exploratory drill work set to commence, Eloro Resources looking increasingly well-placed to capitalize on the increasingly insatiable demand for the minerals fuelling today’s global energy transition.

For more information, visit the company’s website at www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

• Prospera in 2021 launched a new strategy to improve margins and oil and gas production while minimizing environmental impact
• Horizontal well-technology allows for increase in production and Prospera has now abandoned 60 vertical wells as part of its three-year LMRP to reclaim surface land and reduce environmental footprint that will see 200+ vertical wells abandoned
• Prospera this month completed the drilling of four horizontal wells of a ten-well multi-pad infill drill program that can add an additional ~750 bpd at a low decline to Prospera’s current 900+boepd

With more than 42,000 cumulative acres across Cuthbert, Luseland and Heart Hills in Saskatchewan and Red Earth and Pouce Coupe in Alberta, Prospera Energy (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) has the potential to be a significant North American oil and gas producer. In 2021, the company underwent a top-down reorganization, a strategy to realize this potential and do so with best practices regarding protecting the planet. Less than two years into the three-part plan, Prospera is hitting its key performance indicators (“KPIs”), and growing production with an eye on reducing vertical wells.

With its restructuring, Prospera incorporated innovative ESG (environmental, social, and governance) technologies to support a robust Liability Management Ration Program (“LMRP”) to reduce the environmental footprint, Asset Retirement Obligation (“ARO”), and corresponding control expenses and improve margins. LMRPs are an important tool for managing the financial risks associated with oil and gas abandonment and reclamation. They help to protect taxpayers, encourage companies to be more responsible, and ensure that wells and facilities are abandoned and reclaimed in a timely and environmentally responsible manner.

The Canadian government is supportive of LMRPs, offering financial incentives (e.g., tax credits) and loan guarantee programs to assist companies implement programs.

Prospera’s plan is working. 2021 reorganization efforts as phase one of the strategy resulted in production appreciation and liability reduction. Amongst other things, Prospera’s net asset value increased to $72 million from -$3.4 million prior to restructuring. In 2022, phase 2 of the development plan commenced, delivering net income of $3.1 million. In 2024, Prospera is targeting $26.5 million in net income.

From an environmental view, phase two includes capitalizing on Prospera’s large drilling inventory of 150+ targets that are estimated to hold more 400+ million barrels of heavy oil, with only about 9 percent recovered to date. The company has abandoned 60 vertical wells as part of its three-year LMRP that allows PEI to reclaim surface land and reduce environmental footprint. More broadly, the drilling of the new horizontal wells allows Prospera to abandon more than 200 vertical wells.

Phase three includes reducing carbon emissions with upgraded equipment, increasing carbon capture, and the latest technology to further improve profit margin.

This month, Prospera completed the drilling of four horizontal wells of a ten-well multi-pad infill drill program. These wells, which were completed ahead of schedule, encountered structure, and paid as expected with excellent oil shown throughout the pay.

These drilled horizontals are being completed and tied-in to existing infrastructure. Production will be brought on gently initially to optimize recovery due to the heavier fluid properties. The full deliverability can be attained, approximately, over a three-month period. Weather permitting, the next set of four horizontals are to commence within one week.

The ten-well program can approximately add an additional 750 barrels per day (“bpd”) at a low decline to Prospera’s current 900+boepd (barrels of oil equivalent per day). This infill development is intended to accelerate production and recovery to capture the significant heavy oil reserves in place.

Further, a medium-light oil spud will follow the heavy oil horizontal well transformation from vertical wells in the latter part of this month. These slanted drills are awaiting the preparation of the new leases, surface facilities, and connecting pipelines. The medium-light oil development entails six to eight directional wells that can add an additional 600bpd (gross) at 50%, while diversifying Prospera’s product mix and improving margin.

For more information, visit the company’s website at www.ProsperaEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to GXRFF are available in the company’s newsroom at https://ibn.fm/GXRFF

• With EV sales skyrocketing around the world, securing lithium and natural graphite supplies has become a priority for battery manufacturers
• Reflex Advanced Materials has centered its efforts around catering to the lithium and graphite supply chains, with the company announcing that it had fulfilled the penultimate capital payment step needed to secure 100% ownership of its Ontario-based Zigzag lithium project
• The company also took the opportunity to announce the start of core exploratory drill work within the Montana-based Ruby Graphite project

As auto sales staged a significant recovery in the United Kingdom this summer, electric vehicles led the surge. The British Society of Motor Manufacturers and Traders (“SMMT”) revealed that a new battery electric car was registered every sixty seconds, with electric vehicle (“EV”) deliveries rocketing by 87.9 percent relative to the previous year. Moreover, the industry body forecast that new electric vehicle sales momentum would continue its meteoric rise, foreseeing that an electric vehicle would be registered every 50 seconds by year end, rising to one in every 40 by 2024 – a beneficiary of rising uptake levels for EV’s amongst automobile purchasers (https://ibn.fm/5SUjY).

The increase in electric vehicle demand has led to a proportional increase in electric battery sales; automotive lithium-ion battery demand increased by approximately 65 percent to a cumulative 550 GWh in 2022, up from 330GWh in 2021 (https://ibn.fm/YuSYD). The ongoing shift towards renewable energy technologies within the automotive industry has led to a spiraling need to ensure the supplies of key raw materials within the battery manufacturing process – with lithium and graphite ranking chief amongst these. A typical EV battery can contain upwards of 8 kilograms of lithium and up to 50-100 kilograms of graphite (https://ibn.fm/L1WYT); Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF), a British Columbia-based strategic minerals company has centered its corporate mission around locating and developing economic properties within the advanced materials space to cater to the rapidly growing needs of the global electric vehicle industry supply chain.

In mid-August, Reflex Advanced Materials announced that it would be issuing 100,000 new common shares of its capital, the penultimate step needed to fulfil a mineral property option payment agreement the company had entered in 2021 for its Zigzag lithium project. Located near Crescent Lake, Ontario and consisting of eight mining claims totaling approximately 2,710 hectares, the Zigzag lithium project is located deep within an area which has come to be known as the Seymour-Crescent-Falcon lithium belt (https://ibn.fm/laWTE), a geographical phenomenon which has witnessed a number of recent lithium-focused exploration successes over the past few years.

Securing a steady source of lithium has become an increasingly urgent priority for EV battery manufacturers, with Albemarle, the world’s largest lithium producer, recently warning that global lithium demand could outstrip supply by approximately 500,000 tonnes as early as 2030. Despite 45 lithium mines operating globally in 2022, with a further 11 planned to open this year, and an additional seven in 2024, incoming supply of the mineral may not be sufficient to satisfy the sector’s voracious demand.

“You could end up in a crisis situation where the battery companies don’t have the security of (lithium) feedstock,” Stu Crow, chairman of peer lithium producer Lake Resources (https://ibn.fm/0fE9r).

In addition to its lithium-focused ambitions, Reflex Advanced Materials has also sought to boost its graphite supply capacity. One of only a handful of companies catering to the western natural graphite supply chain, Reflex announced that it would shortly begin mobilizing drill equipment for its planned Summer 2023 initial drill program at the Ruby Graphite project in Montana. The Ruby Graphite project, which had earlier produced upwards of 2,400 tons of graphite between 1902 and 1948, will see Reflex carry out over 3,500 meters of core exploratory drill work, with the company announcing that preparatory drill pad construction was already underway (https://ibn.fm/f4l6g).

Paul Gorman, CEO of Reflex Advanced Materials, expressed his enthusiasm about the upcoming drilling campaign, stating, “The mobilization of drill rigs marks an important milestone for Reflex as we advance our exploration efforts at the Ruby Graphite project. We are confident that this drill program will not only confirm the presence of high-grade graphite based on the historical commercial production from the historical Crystal Graphite mine which operated within the current Ruby Graphite project before 1948, but also provide proof-of-concept for moving forward with this important critical and strategic resource.”

For more information, visit the company’s website at www.ReflexMaterials.com.

NOTE TO INVESTORS: The latest news and updates relating to RFLXF are available in the company’s newsroom at https://ibn.fm/RFLXF

• SenesTech, with its proprietary biological solution for efficiently and safely reducing rat populations without killing, represents a remarkable new path to clean cities, businesses, and households
• According to pest industry figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States
• ContraPest offers a unique solution for wastewater facilities because it is non-poisonous and comes in a variety of formats that can help control rat populations where other approaches fall short

SenesTech (NASDAQ: SNES), the rodent fertility control experts and the inventor of the only EPA-registered contraceptive for male and female rats, recently announced that its ContraPest(R) is being deployed in Washington and California through wastewater treatment facilities. Controlling rat infestations presents a unique challenge for wastewater treatment facilities because poisons cannot be introduced into the water supply, and ground-based stations may not be appropriate for many of the facilities.

“Municipalities and government entities comprise a broad and diverse customer base. We are continuously working with these customers, and the pest management professionals who service them, to understand their specific needs and to guide them as to how best to add ContraPest to their integrated pest management system,” said Joel Fruendt, President and CEO of SenesTech (https://ibn.fm/OxgPz). “Wastewater treatment deployment has very specific challenges, and we are able to develop and share deployment protocols utilized by other, similar customers.”

SenesTech strives for clean cities, efficient businesses, and happy households with a product scientifically designed to be effective without killing rats. The company’s first product, ContraPest, applies revolutionary technology to a challenge that has plagued the world since the Middle Ages – the increase of rat populations in urban and agricultural settings. The ContraPest formulation is a highly palatable liquid promoting sustained consumption. It targets the reproductive capabilities of Norway and roof rats, reducing fertility in both male and female rats, bringing populations down, and keeping them down.

SenesTech’s flagship offering, ContraPest, can be used as part of an integrated pest management (“IPM”) program – fitting seamlessly into all IPM programs, reducing reproduction, and magnifying the success of these protocols. It can also be used as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods. ContraPest reduced rat activity by up to 95% in multiple independent field deployments when added to an existing IPM program.

The global rodenticides market is expected to reach a revenue of $7.1 billion by 2027, growing at a CAGR of 5.8%. The market’s growth is attributed to the rising concern for environmental pollution and public health hazards posed by vector-borne diseases, fueling the global demand for rodent control services. The growing population, limited resources, and ecosystem degradation are factors that contribute to the rodents’ ability to survive in different seasons and overpopulation (https://ibn.fm/KrIW0).

Rats are known to spread at least 35 diseases, posing a dangerous risk to public health and safety across the globe. This problem persists despite extensive campaigns to eradicate it, and multiple sources have reported a boom in post-COVID rat populations. Although poison-based control methods sicken rats, they die slowly – and when an animal eats these infected rats, it can also make that animal sick.

ContraPest is available in three unique bait systems – the Ultimate Bait System(TM), Elevate Bait System(TM), and Isolate Bait system(TM). The active ingredients in ContraPest are specifically formulated for rats and break down in their digestive system, resulting in no bioaccumulation or biomagnification in the environment.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• Scinai Immunotherapeutics, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, recently finalized a major rebrand, changing its corporate name from BiondVax Pharmaceuticals
• The rebrand is part of a series of steps to better reflect the company’s new direction and new developments aimed at new scientific breakthroughs
• Amir Reichman took over as CEO in March 2021 and together with the Board of Directors, began implementing a raft of changes aimed at redirecting the company’s focus and diversifying corporate risks
• Scinai is developing a pipeline of novel NanoAbs, with its development pipeline including NanoAbs for the treatment of psoriasis, psoriatic arthritis, asthma, macular degeneration, and Hidradenitis Suppurativa
• The company is intensifying its pipeline development, identifying additional opportunities, and developing novel solutions for large-market unmet needs in 2023 and beyond

When Amir Reichman took over the reins as CEO of the then-named BiondVax Pharmaceuticals in March 2021, he and the Board of Directors embarked on redefining the biotechnology company’s mission and vision. “Our new mission reflects an aspiration to focus on infectious diseases, which leverages [the company’s] core competencies, while ensuring fdiversification of our corporate risks through the establishment of a new, broad product and platform pipeline,” shared Reichman in his first letter to shareholders (https://ibn.fm/oyYwX).

Reichman expressed his intent to rejuvenate the company by implementing a strategy that would diversify the risk along four main axes, including building a pipeline of products for both prevention and treatment of infectious diseases and related illnesses; building a pipeline that would present various routes of drug delivery; building a pipeline that would rely on various platforms; and building a pipeline of products at different stages of clinical development. “If successfully implemented, this strategy would provide [the company] with a robust and diverse multi-dimensional pipeline,” continued Reichman.

Over the two years since that initiation, the company has revamped its senior management team and pharmaceuticals development programs. Additionally, as part of its diversification strategy, the company has expanded into the Contract Development and Manufacturing Organization (“CDMO”) business. Together, these changes represent a fresh start for the company as it journeys toward a new strategic objective. As part of this journey, the company also recently finalized a major rebrand, debuting as Scinai Immunotherapeutics (NASDAQ: SCNI) on Nasdaq as of September 7 this year (https://ibn.fm/5Op2c).

“The biotech sector has been through an extremely challenging time in the past 18-24 months, with low stock prices and scarce capital. We have nevertheless made tremendous progress executing our turnaround program with limited resources and believe we are at the cusp of building a significant and successful company,” commented Reichman in the news release. “We have a sharp commercial focus and a pipeline with blockbuster potential, steeped in science, strong leadership, and an expertly designed technological base. Building on promising data of our initial NanoAb therapies, we look forward to continuing our current pipeline development and also identifying additional opportunities and developing novel solutions for unmet needs in 2023 and beyond.”

Anchoring Scinai’s renewed commercial focus and pipeline development is a robust collaboration with the Max Planck Society, the parent organization of the Max Planck Institute for Multidisciplinary Sciences (“MPI”), and the University Medical Center Göttingen (“UMG”), both in Germany, to develop innovative alpaca-derived nanosized antibodies (“NanoAbs”) (https://ibn.fm/Y1e4d).

The NanoAbs are approximately one-tenth the size of standard monoclonal antibodies (“mAbs”) and are designed to overcome the limitations of existing antibody therapies. For instance, NanoAbs may be effective at extremely low concentrations, which translates to fewer side effects. Moreover, they are expected to have better tissue penetration because of their small size and have demonstrated superior thermostability, which, according to Scinai, could translate to superior shelf life, easier transportation, and more convenient routes of administration. These favorable and unique attributes bolster the company’s efforts to create ‘biobetter’ therapeutics that address large and underserved markets.

In early June, Scinai, in exercise of its broad-based collaboration agreement with Max Planck Society and UMG, signed an exclusive worldwide license agreement to develop and commercialize NanoAbs targeting interleukin-17 (“IL-17”), an immune system cytokine, as treatments for all potential indications, including psoriasis, psoriatic arthritis, and Hidradenitis Suppurativa (https://ibn.fm/twpTX). Beyond that, the company’s NanoAb development pipeline also includes anti-IL-13 and anti-TSLP therapeutics for the treatment of asthma and anti-Ang-2 and anti-VEGF therapeutics for the treatment of age-related wet macular degeneration.

This pipeline approach, Scinai says, affords it considerable flexibility with respect to partnering and extending its assets, opening enhanced potential to generate income through license fees, milestone payment, and royalties, in return for participation in associated R&D costs. To complement its R&D operations, the company also launched Scinai Bioservices, a new business unit that will provide a multitude of CDMO services to support biotechnology companies through process development and GMP manufacturing.

“I’d like Scinai to be internationally recognized for scientific excellence in drug development that is done in the fastest, sharpest way and with the highest quality possible. I want Scinai to be the go-to company for large multinational companies seeking innovative technology and partners that excel in drug development and that can bring their return on investment much faster,” shared Reichman in a video published recently on the company’s YouTube channel (https://ibn.fm/HjOl7).

The name change only reinforces the mission and commitment of Jerusalem-based Scinai Immunotherapeutics to develop, manufacture, and commercialize potential blockbuster immunotherapeutic products for the treatment of infectious diseases and autoimmune disorders. Expect to hear lots more from this innovative biotech company in the months to come.

For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

• Autism Spectrum Disorder (“ASD”) has seen a staggering fourfold increase in the United States over the past two decades
• PaxMedica proudly stands as the sole publicly traded U.S. company singularly dedicated to addressing the challenges posed by Autism
• Our pioneering lead product, PAX-101, has shown significant promise in alleviating core Autism symptoms during early trials
• In 2024, we’re poised to submit a New Drug Application (“NDA”) for PAX-101 to treat Human African Trypanosomiasis (“HAT”), a rare disease also known as African Sleeping Sickness, as part of the Neglected Rare Tropical Disease Program
• With NDA approval, we anticipate the potential to secure a valuable Priority Review Voucher (“PRV”) that could expedite our journey toward FDA recognition for Autism treatment
• Vigorous preparations are underway for clinical trials of PAX-101 in Autism, marking a significant step forward in our mission

In a powerful and informative video message, PaxMedica’s (NASDAQ: PXMD) Chairman and CEO, Howard Weisman, shares a progress report on the critical work being done to address the rising prevalence of Autism Spectrum Disorder (“ASD”) in the United States. This disorder has seen a fourfold increase over the past two decades, underscoring the urgency of PaxMedica’s mission.

PaxMedica stands alone as the only publicly traded company in the U.S. with an unwavering focus on ASD. Weisman highlights the dedication and commitment of the entire PaxMedica team to confront the unique challenges of autism head-on.

Click Here to View the Video 

Weisman further emphasizes the company’s groundbreaking lead product, PAX-101. Early trials of PAX-101 have shown remarkable promise in reducing the core symptoms of Autism, offering newfound hope to countless families affected by this condition.

Looking to the future, PaxMedica has ambitious plans. The company is preparing for an NDA submission of PAX-101 for the treatment of Human African Trypanosomiasis (“HAT”), also known as African Sleeping Sickness, scheduled for 2024. This effort falls under the Neglected Rare Tropical Disease Program, and if approved, could pave the way for PaxMedica to receive a highly valuable Priority Review Voucher (“PRV”), expediting its path to gaining FDA approval for Autism indication.

As PaxMedica prepares for clinical trials of PAX-101 for Autism, Weisman and his team are unwavering in their commitment to bring about transformative change for individuals and families affected by ASD. With optimism and dedication, PaxMedica is focused on delivering innovative solutions and a brighter future for those touched by autism.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

• GEMXX is a mine-to-market enterprise that specializes in the production and distribution of gemstones, like Ammolite, and jewelry on a global scale
• Ammolite is a rare gemstone that exhibits a unique iridescence and is only found in southern Alberta, Canada
• The company recently announced that demand for its Ammolite in jewelry designs by Kenneth Bradley is growing exponentially
• GEMXX plans to expand gemstone and jewelry production by 300% year over year in response to growing demand
• Its shopping channel division is preparing to supply $5.5 million worth of Ammolite gemstones and jewelry over the next 12 months

Although officially recognized by the Coloured Stones Commission of the World Jewellery Confederation (“CIBJO”) as a semi-precious gemstone in 1981 (https://ibn.fm/bfZNW), Ammolite has a long, rich history. Made from the fossilized shells of now-extinct sea creatures known as Ammonites, Ammolite tells the story of lifeforms that existed more than 71 million years ago. In that period, their remains underwent mineralization and transformation induced by tectonic pressure and glacier water, resulting in the “development of an iridescent, rainbow-like coloring that includes red, yellow, green, and blue, the latter hue being the rarest,” according to an article in The Globe and Mail (https://ibn.fm/ryrBq).

While Ammonite fossils are scattered around the world, Ammolite gemstone is only found on the eastern slopes of the Rocky Mountains – within the Bearpaw geologic formation – in southern Alberta, Canada, making it one of the rarest gems on earth and sought after around the world. The visual allure of Ammolite stems from the fact that it exhibits iridescence and vibrance, which result from the stone’s multiple layers. However, because of these layers, Ammolite is quite fragile and needs to be carefully handled while mining and polishing (https://ibn.fm/B88KL), considerations that guide the meticulous work of the experienced gemstone cutters and jewelry designers at GEMXX (OTC: GEMZ), who have catapulted the company to the upper echelons of finished Ammolite production.

GEMXX is a mine-to-market enterprise specializing in the production and distribution of gemstones and jewelry on a global scale. In the domain of Ammolite mining and processing, the company stands out as the leading producer of top-quality finished Ammolite, surpassing competitors both in terms of production capacity and quality (https://ibn.fm/KbW60). GEMXX relies on a world-class team of gemstone cutters and jewelry designers whose expertise continues to increase the demand for its products.

Just recently, GEMXX announced that demand for its Ammolite in jewelry designs by Kenneth Bradley is exponentially growing. One of the world’s most recognized Ammolite experts, Bradley founded Canadian Ammolite Gems by Kenneth Bradley, an Ammolite jewelry collection. He hosts live, on-air events showcasing uniquely beautiful GEMXX Ammolite gemstones in jewelry by Kenneth Bradley designs and will continue to host multiple Ammolite events annually featuring stunning Ammolite gems curated by GEMXX gemstone cutters (https://ibn.fm/2qms4).

“It is my opinion that GEMXX supplies the finest Ammolite in the world, and that is why I have selected them as the exclusive supplier for my Ammolite jewelry,” commented Bradley.

GEMXX plans to expand gemstone and jewelry production by 300% year over year in response to growing demand, tapping into its proven Ammolite reserves, currently valued at more than $600 million. On its part, the company’s shopping channel division is preparing to supply $5.5 million worth of Ammolite gemstones and jewelry over the next 12 months.

“This is a fundamental step in the company’s expansion plans. GEMXX Ammolite products will now have an expanded on-air presence in the United States, Canada, and Australia,” said Jay Maull, GEMXX’s CEO.

To facilitate this expansion, the company aims to raise $6 million in investment funding through a fully qualified Regulation A (“Reg A”) offering. “This will allow the company to break ground on a new, large-scale Ammolite mine, expand current goldmine operations, and cater to the ever-increasing global demand for its products,” GEMXX says in its investor presentation (https://ibn.fm/bXlQu).

Those interested in participating through Reg A financing are encouraged to visit the company’s investor page (https://ibn.fm/ZWx9a) or contact the company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks
• This technology has also shown positive impacts in obese diabetic-conditioned animals from its DIAB-A22-1 pre-clinical study
• The NIC-H22-1 human nicotine study also demonstrated a statistically significant difference to achieve maximum blood saturation
• These results have demonstrated DehydraTECH’s potential while propping it to take advantage of vastly untapped markets with potential for growth in the coming years

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for its growing range of applications, which include oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. The progress achieved thus far has been the product of years of clinical and pre-clinical research, all of which reflect management’s confidence in the company’s direction and technology.

As of the three months ended May 31, 2023, the company had increased its research and development (“R&D”) expenses by 118% year-over-year, primarily focused on the execution of hypertension, oral nicotine, and diabetes studies (https://ibn.fm/EVk0p). This devotion of a significant proportion of its resources reflects the company’s intent to establish areas of investigation for commercial pursuits while bringing it closer to tapping into vastly untapped markets with the potential for growth in the coming years.

The investments have paid off, with Lexaria having come a step closer to submitting its Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial with the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/zZ96p). So far, previous clinical trials have shown DehydraTECH-processed CBD’s ability to lower blood pressure in patients over multiple weeks, a tremendous achievement for the company and for its technology.

“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” noted Chris Bunka, Lexaria’s CEO (https://ibn.fm/G9dm6).

This success has been replicated in other studies, most notably diabetes. In Lexaria’s pre-clinical diabetes study, DIAB-A22-1, conducted in obese diabetic-conditioned animals, DehydraTECH-CBD yielded successful results showing positive impacts on blood glucose levels, overall body weight, locomotor activity, in addition to triglyceride and blood urea nitrogen levels. With the American Diabetes Association (“ADA”) estimating the number of Americans with diabetes at 37.3 million as of 2019, there is a dire need for viable treatment options, and Lexaria is looking to address that (https://ibn.fm/A2R5W).

Lexaria’s DehydraTECH has also proven its superiority and advantage over traditional oral delivery methods in the nicotine replacement market. Its NIC-H22-1 human nicotine study demonstrated a statistically significant difference between the time taken to achieve maximum blood saturation levels (“Tmax”) for DehydraTECH-nicotine at 2.3 and 3.1 minutes faster than alternatives currently in the market. In addition, DehydraTECH-nicotine represented a 15% and 20% faster response to achieve maximum blood saturation, a feat that few other players in the market have achieved.

“Within just five short years of R&D and product development, Lexaria has been able to develop an oral nicotine product that meets or exceeds the performance of the world’s leading existing brands,” noted Mr. Bunka.

“This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths,” he added (https://ibn.fm/kxfsA).

Even with its achievements so far, Lexaria remains committed to pushing the envelope regarding the research and development of its DehydraTECH technology. So far, it has demonstrated its incredible potential across various areas of application as well as its viability in the market. The consistent push for further development reflects Lexaria’s understanding of its mission and commitment to creating shareholder value.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

by Elaine Mendonça

On September 28, 2023, Clene Inc. (NASDAQ: CLNN) made an exciting announcement regarding their groundbreaking research on the investigational drug CNM-Au8. In a scientific paper published in the esteemed journal Small, Clene Inc. revealed the catalytic mechanism of action behind the therapeutic properties of CNM-Au8.

The study showcased the remarkable neuroprotective abilities of CNM-Au8, attributing its success to its unique catalytic activity. When exposed to toxins that typically lead to neuronal death, CNM-Au8 treatment exhibited a remarkable ability to promote cell survival and preserve the intricate network of neurites.

To truly understand the underlying mechanisms responsible for CNM-Au8’s neuroprotective function, extensive studies were conducted. These studies focused on characterizing the catalytic reactions facilitated by CNM-Au8, aiming to unravel how it effectively regulates cellular health and metabolism. The findings were nothing short of groundbreaking, shedding light on the exceptional therapeutic potential of CNM-Au8.

The distinct mechanism of action exhibited by CNM-Au8, coupled with its wide applicability in preserving neuronal health, positions it as a promising new treatment for various neurodegenerative diseases. This research opens up exciting possibilities for addressing multiple assaults on neuronal health and offers hope for patients worldwide.

Clene Inc. (NASDAQ: CLNN) Stock Performance and Financial Indicators: September 28, 2023 Analysis

CLNN stock had a relatively stable performance on September 28, 2023, with a previous close of $0.53 and an open of $0.52. Throughout the day, the stock fluctuated within a range of $0.52 to $0.55. The trading volume was 533,547 shares, which is slightly higher than the average volume of 528,357 shares over the past three months. The market capitalization of CLNN stands at $59.5 million.

Looking at the financial indicators, CLNN has experienced significant challenges in terms of earnings growth. The earnings growth for the previous year was -190.01%, indicating a substantial decline. However, there is no available information on earnings growth for the current year or the next five years. The revenue growth for the last year was also negative, with a decline of 34.58%.

The price-to-earnings (P/E) ratio for CLNN is not provided (NM), suggesting that the company may have negative earnings or no earnings at all. The price/sales ratio is 137.85, indicating that investors are willing to pay a premium for each dollar of sales generated by the company. The price/book ratio is 10.71, which suggests that the stock may be overvalued based on its book value.

Clene Inc. (NASDAQ: CLNN) operates in the health technology sector, specifically in the pharmaceuticals: major industry.

The next reporting date for CLNN is November 7, 2023. Analysts forecast an earnings per share (EPS) of -$0.10 for this quarter. The annual revenue for the previous year was $473,000, while the annual profit was -$29.9 million. The net profit margin for CLNN is a staggering -6,325.16%, indicating significant losses.

Investors should carefully consider these factors before making any investment decisions regarding CLNN stock.

CLNN Stock Shows Impressive Performance with Potential for Significant Growth: Analysts Median Target Estimate

CLNN stock had an impressive performance on September 28, 2023, based on the information provided by CNN Money. The 12-month price forecasts from six analysts for Clene Inc. had a median target of $5.00, with a high estimate of $10.00 and a low estimate of $4.00. This median estimate represents a remarkable increase of 825.93% from the last recorded price of $0.54.

The consensus among the six polled investment analysts is to buy stock in Clene Inc., and this rating has remained steady since September. This indicates a positive sentiment towards the company’s future prospects.

It is important to note that the stock’s current performance is not solely based on the information provided for September 28, 2023. The data source does not provide specific details about the stock’s performance on that particular day. However, the 12-month price forecasts and the consensus among analysts suggest a positive outlook for Clene Inc.

In terms of financials, the current quarter’s earnings per share for Clene Inc. were reported at -$0.10. Additionally, the company’s sales for the same quarter amounted to $117.8K. These figures indicate that Clene Inc. may be experiencing some financial challenges in the short term.

Investors should keep an eye on Clene Inc.’s upcoming reporting date, which is set for November 7. This report may provide more insights into the company’s financial performance and future prospects.

Overall, the information provided suggests that Clene Inc.’s stock has the potential for significant growth, as indicated by the high median target estimate from analysts. However, investors should carefully consider the company’s financial performance and any upcoming reports before making investment decisions.

For more information on Clene visit Clene Inc. (NASDAQ: CLNN)

Third-Party Content

The STBN website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the STBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of STBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and STBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by STBN providing you with this internet portal that makes accessible to you the ability to view third party content through the STBN site, STBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. STBN expressly disclaims liability relating to such third-party content. STBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, STBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.stockstobuynow.com/disclaimer/.

The disclaimers on the STBN website are applicable to all content provided by STBN, wherever published or re-published are at: https://www.stockstobuynow.com/disclaimer/